

REMARKS

Claims 18-24 and 27 are pending in the application. Claim 18 has been amended to recite that the compound comprising the immunomodulatory moiety has greater or reduced immunostimulatory effect than it would have if it lacked the immunomodulatory moiety. Support for this amendment can be found throughout the specification, for example, at page 7, lines 15 through 21. No new matter has been added.

Claims 18-24 and 27 are rejected for nonenablement. Applicants respectfully disagree. As argued in response to the previous Office Action, which is incorporated herein by reference, and as taught in the specification, the immunomodulatory effects of the modifications taught in the specification is readily determined. In addition, in the related case Serial No. 10/365,834, claims of similar scope were found to be enabled. Applicants understand that it has been well established that each application is treated on its own merits. However, the current claims, as amended, recite a method of inducing an immune response comprising administering the composition as recited in the claims of Serial No. 10/365,834. Accordingly, Applicants respectfully submit that the specification enables the claimed invention and request that this rejection be withdrawn.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

Respectfully submitted,

Dated: 1-19-06
Keown & Associates
500 West Cummings Park
Suite 1200
Woburn, MA 01801
Telephone: 781/938-1805
Facsimile: 781/938-4777

By Joseph C. Zuccherro
Joseph C. Zuccherro
Registration No. 55,762